Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CCL2 | P13500 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418352 | 0.93 | BRD4 (0.38) | BRD4CCL2HTR2AKDM4ELMNA | |
| SCHEMBL11348748 | 0.79 | BRD4 (0.41) | BRD4CCL2HTR2AKDM4ELMNA | |
| SCHEMBL18814602 | 0.73 | — | — | |
| SCHEMBL18516527 | 0.73 | FAAH (0.31) | — | |
| SCHEMBL10390576 | 0.73 | BRD4 (0.41) | BRD4CCL2HTR2AKDM4ELMNA | |
| SCHEMBL517047 | 0.69 | — | — | |
| SCHEMBL15615571 | 0.68 | DRD2 (0.30) | DRD2 | |
| SCHEMBL24896198 | 0.68 | HTR2A (0.38) | BRD4CCL2HTR2AKDM4ELMNA | |
| SCHEMBL7772311 | 0.68 | HTR2A (0.38) | BRD4CCL2HTR2AKDM4ELMNA | |
| SCHEMBL8330852 | 0.67 | HTR2A (0.36) | BRD4CCL2HTR2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 797 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702032-A1 | MODIFICATION OF PSEUDOURIDINE | Ludwig Institute for Cancer Research Ltd (CH) | 2026-03-04 | — | — | EP | claimed |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| US-12527871-B2 | Click chemistry capturable platinum-based antineoplastic agents | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20250376724-A1 | LINEAR DOUBLE STRANDED DNA COUPLED TO A SINGLE SUPPORT OR A TAG AND METHODS FOR PRODUCING SAID LINEAR DOUBLE STRANDED DNA | CureVac SE (DE) | 2025-12-11 | — | — | US | claimed |
| EP-4648800-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4648801-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| US-20250289846-A1 | METHODS OF PURIFYING ANTIBODY-NUCLEIC ACID CONJUGATES | BRUKER SPATIAL BIOLOGY, INC. | 2025-09-18 | — | — | US | claimed |
| US-20250288685-A1 | BIOMATERIALS FOR IMPROVING BRAIN HEALING AFTER STROKE AND METHODS OF USING SAME | UNIV DUKE (US) | 2025-09-18 | — | — | US | claimed |
| WO-2017218891-A1 | SITE-SPECIFIC CROSSLINKING OF ANTIBODIES | Life Technologies Corporation (US) | 2017-12-21 | — | — | WO | claimed |
| WO-2017212329-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-14 | — | — | WO | claimed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | claimed |
| EP-3204425-A2 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | Genzyme Corporation (US) | 2017-08-16 | — | — | EP | claimed |
| US-20170216460-A1 | GLYCOPEPTIDE FOR CONTRAST AGENT TARGETING CANCER CELLS AND CONTRAST AGENT KIT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-08-03 | — | — | US | claimed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | claimed |
| WO-2016183387-A1 | COMPOSITIONS AND METHODS FOR MAKING ANTIBODY CONJUGATES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-11-17 | — | — | WO | claimed |
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORPORATION | 2016-05-19 | — | — | US | claimed |
| WO-2016057769-A2 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORPORATION (US) | 2016-04-14 | — | — | WO | claimed |
| US-20130281656-A1 | METHODS FOR LABELING A SUBSTRATE HAVING A PLURALITY OF THIOL GROUPS ATTACHED THERETO | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. BOYD GRADUATE STUDIES RESEARCH CENTER (US) | 2013-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281656-A1 | METHODS FOR LABELING A SUBSTRATE HAVING A PLURALITY OF THIOL GROUPS ATTACHED THERETO | SQOR, NQO2, DAO | BRD4 3825/4885CCL2 3281/4885HTR2A 2249/4885 |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | BRD4 2631/4885CCL2 1305/4885HTR2A 2014/4885 |
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | CD2BP2, B3GAT3, SIGLEC7 | BRD4 4347/4885CCL2 564/4885HTR2A 4624/4885 |
| US-12527871-B2 | Click chemistry capturable platinum-based antineoplastic agents | LPXN, ILK, PDCD10 | BRD4 2045/4885CCL2 56/4885HTR2A 4304/4885 |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | MGAT3, GALE, GPI | BRD4 1008/4885CCL2 1336/4885HTR2A 4543/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | BRD4 4053/4885CCL2 2477/4885HTR2A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.